TECHNOLOGY-BASED
pharmaceutical company Verseon
has announced that it has
developed a new class of oral,
highly selective, direct thrombin
inhibitors which have demonstrated
reduced risk of major bleeding in
comparison with current novel oral
anticoagulants (NOACs).
The announcement was
presented at the Biotech Showcase
Conference in San Francisco this
week.
The early pre-clinical studies have
indicated that the new compounds
have equivalent or better
therapeutic potential, the company
said, adding that they are still a few
years from marketing approvals.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.